Chi phí – thỏa dụng của regorafenib ở người bệnh ung thư biểu mô tế bào gan tiến triển sau sorafenib: bằng chứng từ một quốc gia thu nhập trung bình thấp
Value in Health Regional Issues · 2026 · Tập 57 · 101657
DOI Trang nguồn Toàn văn RIS BibTeX
Tóm tắt
OBJECTIVES: To analyze the cost-utility of regorafenib as a second-line treatment for patients with hepatocellular carcinoma who had progressed on sorafenib in Vietnam from a perspective of the public third-party payer.
METHODS: We conducted a cost-utility analysis using a three-health-state partitioned survival model over a 5-year time horizon with a monthly cycle length. Clinical data for regorafenib were obtained from the RESORCE clinical trial, whereas cost data were sourced from regulatory agency websites and consultations with clinical experts in Vietnam. One-way sensitivity, probabilistic sensitivity, and scenario analyses were performed to explore uncertainty. A 3% discount rate was applied to both costs and health outcomes.
RESULTS: Base-case results showed that, compared with best supportive care, regorafenib provided an additional 0.36 life-years (LYs) equaling to 0.26 quality-adjusted life-years (QALYs), with an incremental cost of 122.6 million Vietnam dong; resulting in an incremental cost-effectiveness ratio of 396.5 million Vietnam dong per QALY, or 3.9 times the gross domestic product per capita. At a willingness-to-pay threshold of 3 times the gross domestic product per capita, regorafenib had a 21.7% probability of being cost-effective. When the health insurance coverage rate for regorafenib was 70% or lower, the incremental cost-effectiveness ratio decreased to below this threshold.
CONCLUSION: With significant improvement in terms of progression-free survival or overall survival, regorafenib gained more LYs and QALYs compared with best supportive care. When the health insurance coverage rate for regorafenib was 70% or lower, regorafenib was cost-effective from the perspective of the third-party payers.
Nguyên văn tóm tắt của bài gốc đăng trên Value in Health Regional Issues.
Thông tin HTA
| Loại tài liệu | Nghiên cứu đánh giá kinh tế y tế |
|---|---|
| Mức độ liên quan HTA | Nghiên cứu kinh tế y tế |
| Loại công nghệ | Dược phẩm |
| Phương pháp kinh tế | Phân tích chi phí–hữu ích |
| Kết luận chính | With significant improvement in terms of progression-free survival or overall survival, regorafenib gained more LYs and QALYs compared with best supportive care. When the health insurance coverage rate for regorafenib was 70% or lower, regorafenib was cost-effective from the perspective of the third-party payers. |
| Nguồn tài trợ | Bayer (theo thông tin tài trợ công bố trên Europe PMC). |
| Truy cập | Toàn văn truy cập mở đã xác minh |
| Giấy phép | CC BY-NC-ND |
| Mã HERAC | HERAC-PUB-2026-04 |
Thông tin thư mục do HERAC biên tập và đối chiếu với trang nguồn. Vui lòng đọc và trích dẫn tài liệu gốc.